- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2010.
- Why 3/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, AdComm) is scheduled for Victoza in the next ~12 months. The drug has been approved since 2010 and is facing established generic competition. For Novo Nordisk (NVO), Victoza is a rapidly declining legacy product contributing <1% of total revenue, making any single data point for this one drug incapable of meaningfully moving the stock.
Victoza is a tail-end asset with no upcoming binary catalyst. For Novo Nordisk investors, watch GLP-1 class dynamics, generic liraglutide erosion is already priced in, but the FDA's shortage status (still active as of Oct 2026) could create short-term supply-driven revenue variability. The real stock drivers are semaglutide (Ozempic/Wegovy) competitive positioning and the oral Wegovy rollout, not this legacy product.
Price Chart
Executive Summary
Victoza (liraglutide) is Novo Nordisk's first-generation GLP-1 receptor agonist, FDA-approved since January 2010 for type 2 diabetes (adults and children 10+) and expanded in 2017 to reduce cardiovascular risk. The drug has been a commercial blockbuster in its prime but is now deep into its decline phase: generic competition arrived in 2024 (Teva authorized generic in June, Hikma ANDA in December), and Victoza revenue fell ~45% year-over-year to DKK 3.0 billion in FY2025. For Novo Nordisk (NYSE: NVO, $38.69), Victoza represents less than 1% of total revenue, the company's massive GLP-1 franchise is now dominated by semaglutide products (Ozempic, Wegovy, Rybelsus), which generated $24.0B in 2025. No upcoming FDA catalysts or PDUFA dates exist for Victoza, and the stock's trajectory depends on Wegovy/Ozempic competitive dynamics and pipeline assets, not this mature legacy product.
How It Works
Victoza (liraglutide) is a once-daily injectible medication that mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). When blood sugar rises after eating, it sshows the pancreas to release more inslin, slows down food emptying from the stomach, and reduces appetite. This combination helps control blood sugar in people with type 2 diabetes and has been shown to lower the risk of heart attack, stroke, and cardiovascular death.
Trial Status
Victoza completed all required Phase 3 trials for initial FDA approval in 2010. A post-market cardiovascular outcomes trial (LEADER) supported the CV risk-reduction label expansion in 2017. Pediatric approval in 2019 was based on the first Phase 3 trial of a non-insulin diabetes drug in children (NEJM 2019). All patent-protected clinical development is conplete; no new pivotal trials are running for this indication.
The Two-Sided Case
Upcoming Catalysts
- None scheduled. Victoza is an approved, off-patent legacy drug with no pending FDA decisions, label-expansion applications, or registrational readouts in the next ~12 months.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
NOVO NORDISK A S COURT-RULING NVO ·Originating report